Close menu




April 30th, 2021 | 08:40 CEST

Nvidia, NSJ Gold, Coinbase - How to counter inflationary pressures?

  • Investments
Photo credits: pixabay.com

Historically, tangible assets have performed poorly compared to equity investments. According to a Bank of America study, that may now be starting to change. The constant printing of money is fueling inflation. Tangible assets such as real estate, precious metals or collectibles are suitable as a hedge against inflation. While the first two categories are self-explanatory, there are new categories, especially in collectibles. The familiar areas are wine and art objects. Recent additions are cryptocurrencies, first and foremost Bitcoin, of course. In the course of this hype, high-performance graphics cards have also become rare. These are now traded at more than double the recommended retail price. So today, we take a look at Nvidia, NSJ Gold and Coinbase.

time to read: 2 minutes | Author: Armin Schulz
ISIN: US67066G1040 , CA62973P1071 , US19260Q1076

Table of contents:


    Nvidia - Full steam ahead

    Nvidia is the market leader in the graphics processing unit (GPU) sector. In the meantime, however, it is no longer only active in graphics cards but also uses the computing capacity of GPUs in the field of artificial intelligence (AI), such as in deep learning. Companies such as Baidu, Microsoft and Facebook are taking advantage of this.

    Looking at Nvidia's annual report, 95% of its revenue comes from the GPU market. 51% comes from gaming, 27% from high-performance data centers like AI, and 11% from professional visualization. The Company also wants to position itself in the CPU market, which was previously reserved for Intel and AMD. If successful, another revenue stream is created.

    The share knows only one direction since the Corona Crisis and that is north. On the one hand, the demand increased due to Corona, and on the other hand, the graphics cards are used for mining cryptocurrencies. As long as bitcoin has such a high value, graphics cards will remain scarce on the market and Nvidia will continue its success story.

    NSJ Gold - Young explorer with potential

    NSJ Gold is only very freshly listed on the stock exchange and issued around 9.1 million shares at CAD 0.2 with the IPO. The Company has secured the rights to the Golden Hills project in Arizona and intends to mine gold and copper there. The property is 8.5 square kilometers and is surrounded by copper and gold mines. Historic drilling in 2010 has already found gold and copper just a few meters below the surface. The Golden Hills project has 7 patented and 94 unpatented claims.

    On April 15, the Company released the first update on its exploration drilling. Already 5 holes have been drilled around the identified gold and copper discoveries. The rock is similar to what was drilled when the deposits were first found. The first round of drilling is expected to be completed by the end of April. Samples will then be taken for analysis. A positive factor that investors should not underestimate is the Company's management board. It is staffed with experienced people from the mining sector, and with Richard Kern, they have the man on board who knows the Golden Hills area like the back of his hand.

    At the beginning of NSJ Gold's IPO, the stock reached its all-time high at CAD 0.37 and then fell back to the issue price of CAD 0.2. The share is currently trading at around CAD 0.23 and so one can be in at almost the cost price. If the analysis of the samples confirms the initial findings, nothing should stand in the way of a rising share price.

    Coinbase - Between many imponderables

    The stock market launch for Coinbase was more than successful. The issue price was USD 250 and it already went up to over USD 429 on the first trading day. Since then, there has been profit-taking; even the CEO sold around 750,000 shares.

    A lot has happened since then, the bitcoin price dropped sharply and now there are growing calls for crypto exchanges to collect more information about customers. According to Reuters, a US group of experts is calling for much stronger regulation of cryptocurrencies. It is hoped that this will curb extortion from the Internet.

    Revenue and profit for Coinbase result, among other things, from the high bitcoin price. If this falls, then sales and profits decline. Many users of Bitcoins like the anonymity, and with stronger regulation, this will undoubtedly impact trading volumes. So the investment in Coinbase is closely linked to the bitcoin price. Bitcoin's last setback saw it drop 80% before moving to new all-time highs. Bitcoin will remain volatile.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read